New antibiotic and method for developing it exploits microbes' natural environment
the ONA take:
Researchers have discovered a powerful new antibiotic, teixobactin, using an unusual method. Teixobactin was tested in mice and easily cured severe infections, with no side effects.
Testing in humans will not begin for approximately 2 years, according to the researchers; therefore, its safety and effectiveness are not known at this time.
Even if the drug passes all the tests, it may not be available for 5 or 6 years. Importantly, the researchers are excited about the method used to produce this antibiotic because it has the potential to lead to the discovery of more natural compounds to fight infections and cancer.
In this method, drugs are extracted from bacteria that live in dirt. The method exploits the biological antibiotics found in the natural environment—the dirt—where microbes exist.
The process involves diluting a soil sample and placing it on a specialized device. The device is then placed into a box full of the same soil the sample came from, thereby tricking the bacteria into growing into a colony in its natural environment. The method may help resolve two significant issues in global health: the increase in infections that resist commonly used drugs and the lack of new antibiotics to replace those that are no longer effective.
Researchers have discovered a powerful new antibiotic, teixobactin, using an unusual method.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|